Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.48 |
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.48 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.48 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.46 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29711728 | 1.00 | TRPV1 (0.48) | TRPV1LMNAMAPTGAARAB9A | |
| SCHEMBL29371081 | 1.00 | TRPV1 (0.48) | TRPV1LMNAMAPTGAARAB9A | |
| SCHEMBL2941795 | 0.94 | TRPV1 (0.49) | TRPV1LMNAMAPTGAARAB9A | |
| SCHEMBL2950190 | 0.92 | MAPT (0.54) | TRPV1LMNAMAPTGAARAB9A | |
| SCHEMBL2950017 | 0.90 | TRPV1 (0.47) | TRPV1LMNAMAPTGAARAB9A | |
| SCHEMBL23607575 | 0.90 | KCNK3 (0.48) | LMNAMAPTRAB9AKCNK3KCNK9 | |
| SCHEMBL22339754 | 0.89 | TRPV1 (0.46) | TRPV1LMNAMAPTGAARAB9A | |
| SCHEMBL17154497 | 0.88 | LMNA (0.52) | LMNAMAPTGAARAB9AKCNK3 | |
| SCHEMBL22339738 | 0.87 | LMNA (0.57) | TRPV1LMNAMAPTGAARAB9A | |
| SCHEMBL2950197 | 0.86 | RET (0.46) | KCNK3KCNK9S1PR1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016020434-A1 | METHOD FOR EXPANDING IMMUNE CELLS | Johann Wolfgang Goethe-Universität (DE) | 2016-02-11 | — | — | WO | claimed |
| EP-2982745-A1 | Method for expanding immune cells | Johann Wolfgang Goethe-Universität, Frankfurt am Main (DE) | 2016-02-10 | — | — | EP | claimed |
| US-9034387-B2 | Intrinsically fluorescent carbon nanospheres and a process thereof | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH (IN) | 2015-05-19 | — | — | US | claimed |
| US-20060167107-A1 | Modulators (inhibitors/ activators) of histone acetyltransferases | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH (IN) | 2006-07-27 | — | — | US | claimed |
| US-12180524-B2 | Epigenetic modification of fungi and uses thereof | UNIVERSITY OF SOUTH FLORIDA (US) | 2024-12-31 | — | — | US | disclosed |
| US-12116365-B2 | Heterocyclic compounds and uses thereof | Opna Bio SA (CH) | 2024-10-15 | — | — | US | disclosed |
| US-20230265432-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE MYELOID LEUKEMIA | Sanford Burnham Prebys Medical Discovery Institute | 2023-08-24 | — | — | US | disclosed |
| US-20230190718-A1 | METHODS FOR THE TREATMENT OF PANCREATITIS AND PREVENTION OF PANCREATIC CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-06-22 | — | — | US | disclosed |
| CN-111194318-B | Solid forms of compounds for modulating kinases | OPNA生物公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-3675880-B1 | TARGETED EPIGENETIC THERAPY FOR INHERITED AORTIC ANEURYSM CONDITION | UNIV JOHNS HOPKINS (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-4153174-A1 | METHODS FOR THE TREATMENT OF PANCREATITIS AND PREVENTION OF PANCREATIC CANCER | Board of Regents, The University of Texas System (US) | 2023-03-29 | — | — | EP | disclosed |
| US-20220356183-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2022-11-10 | — | — | US | disclosed |
| EP-2054524-A2 | METHOD FOR TREATMENT OF PROSTATE CANCER AND SCREENING OF PATIENTS BENEFITING FROM SAID METHOD | Valtion Teknillinen Tutkimuskeskus (FI) | 2009-05-06 | — | — | EP | disclosed |
| US-20090076155-A1 | MODULATORS (INHIBITORS/ACTIVATORS) OF HISTONE ACETYLTRANSFERASES | KUNDU TAPAS KUMAR | 2009-03-19 | — | — | US | disclosed |
| WO-2008042795-A2 | HISTONE ACETYLE TRANSFERASE ACTIVATORS AND HISTONE DEACETYLASE INHIBITORS IN THE TREATMENT OF ALCOHOLISM | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008023087-A2 | METHOD FOR TREATMENT OF PROSTATE CANCER AND SCREENING OF PATIENTS BENEFITING FROM SAID METHOD | VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) | 2008-02-28 | — | — | WO | disclosed |
| US-7332629-B2 | Modulators (inhibitors/activators) of histone acetyltransferases | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH (IN) | 2008-02-19 | — | — | US | disclosed |
| US-20060167107-A1 | Modulators (inhibitors/ activators) of histone acetyltransferases | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH (IN) | 2006-07-27 | — | — | US | disclosed |
| EP-1590318-A2 | MODULATORS (INHIBITORS/ACTIVATORS) OF HISTONE ACETYLTRANSFERASES | Jawaharlal Nehru Centre For Advanced Scientific Research (IN) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004053140-A2 | MODULATORS (INHIBITORS/ACTIVATORS) OF HISTONE ACETYLTRANSFERASES | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH (IN) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116365-B2 | Heterocyclic compounds and uses thereof | CYP11B2, CYP11B1, UGT2B7 | TRPV1 1373/4885LMNA 805/4885MAPT 2326/4885 |
| US-20060167107-A1 | Modulators (inhibitors/ activators) of histone acetyltransferases | EP300, HDAC1, KAT2A | TRPV1 3293/4885LMNA 4079/4885MAPT 1900/4885 |
| US-20220356183-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, CYP11B1, UGT2B7 | TRPV1 1373/4885LMNA 805/4885MAPT 2326/4885 |
| US-12180524-B2 | Epigenetic modification of fungi and uses thereof | EHMT1, EHMT2, DOT1L | TRPV1 4872/4885LMNA 1014/4885MAPT 3416/4885 |
| US-20090076155-A1 | MODULATORS (INHIBITORS/ACTIVATORS) OF HISTONE ACETYLTRANSFERASES | KAT2A, HDAC5, HAT1 | TRPV1 2533/4885LMNA 2767/4885MAPT 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.